This article is more than 5 years old. Information may no longer be current.

FDA clears investigational new drug application for potential rosacea treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has cleared an investigational new drug application to evaluate a potential topical treatment for rosacea, according to developer Signum Dermalogix.

SIG990, an isoprenylcysteine (IPC) analog that modulates toll-like receptor and G-protein signaling, safely treats erythema and inflammatory lesions and may provide an improved therapeutic option for patients with rosacea, according to a press release. The topical therapy has demonstrated “promising results in several in vitro cell-based assays and efficacy in in vivo topical inflammatory animal models,” the release said.

“We continue to make significant progress and are well positioned to advance the development of our IPC compounds in dermatology,” Maxwell Stock, CEO of Signum Dermalogix, said in the release. “I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects.”